Skip to content
LaunchIndex
Browse/2026/09/zyx-ai.com

智御星 · AI 免疫药物发现

zyx-ai.com

LaunchIndex first observed 智御星 · AI 免疫药物发现 (zyx-ai.com) live on 3 September 2026. View its launch screenshot, category, and verification evidence.

Visit zyx-ai.com External site · Last checked September 03, 2026
Screenshot of zyx-ai.com
Captured September 03, 2026 09:29 as part of the recorded launch evidence.
Observed launch story

A launch record built from evidence.

智御星 · AI 免疫药物发现 (zyx-ai.com) was first observed live on 3 September 2026.

AI-powered immune drug discovery platform that links disease mechanisms, generative AI, and experimental validation to accelerate oncology drug development.

Its profile is classified as Saas within Technology / Artificial intelligence.

Recorded evidence

What the launch signal contained.

First observed live
Previous state
No prior non-live observation
Last verified
Canonical host
zyx-ai.com
Category
Technology / Artificial intelligence
Website type
Saas
Observed title
智御星 · AI 免疫药物发现
Observed description
智御星:以免疫智能体与实验闭环,推动下一代肿瘤免疫药物发现。
Detected technologies
None detected
Screenshot captured
Evidence source
Browser observation · Local
Evidence confidence
93%
HTTP status
200
Share this record

A canonical launch profile for zyx-ai.com.

Share the profile directly or add the optional badge to the website. A badge is never required for inclusion, verification, or ranking.

Share profile
Website owner

Is this your website?

Claim this profile to add verified owner information.

Claim website
Community signal

What do you make of this launch?

Vote on the site and leave a short note for other people exploring the new web.

0Up
0Down

Join the discussion

Sign in with Google to vote or comment.

Sign in to participate

Comments

0 comments
No comments yet

Be the first to leave a useful observation.

Report an issueFlag spam, illegal or harmful content, or inaccurate information.

Reports are private and reviewed by the moderation team. No sign-in is required, so this report will be anonymous.

Private to moderators · 10–2,000 characters